Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression

Background IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has serious outcomes with end-stage renal disease developing in 30–50% of patients. The diagnosis requires renal biopsy. Due to its inherent risks, non-invasive approaches are needed.